Literature DB >> 6983473

Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg positive chronic liver disease.

G Mieli-Vergani, D Vergani, B Portmann, Y White, I Murray-Lyon, J H Marigold, I Woolf, A L Eddleston, R Williams.   

Abstract

Lymphocytes from 39 patients with HBsAg positive chronic liver disease were incubated with their own hepatocytes to investigate mechanisms of lymphocyte-mediated liver damage. Cytotoxicity was significantly increased in 46% overall, and in 73% of those with chronic active hepatitis. Unlike HBsAg negative chronic active hepatitis where only non-T cells were cytotoxic, HBsAg positive patients had both cytotoxic T and non-T cells. A purified liver membrane complex (LSP) and aggregated IgG both blocked non-T cytotoxicity without affecting T cell cytotoxicity; this suggests that the former is probably an antibody-dependent cell-mediated reaction against normal membrane components. This was confirmed in preliminary studies which demonstrated that preincubation of hepatocytes with the F(ab)2' fragment of an anti-human IgG reduced non-T lymphocyte cytotoxicity. T-cell cytotoxicity was restricted to HBeAg-positive patients, suggesting a relationship between T-cell cytotoxicity and viral replication. Purified HBsAg, however, blocked cytotoxicity in only three of 11 cases. Non-T lymphocytes reacting with normal membrane components may contribute to liver damage in both 'autoimmune' and virus-associated chronic liver disease, whereas cytotoxic T-cells, probably reacting with viral determinants, are exclusive to those with viral replication.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6983473      PMCID: PMC1419850          DOI: 10.1136/gut.23.12.1029

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

Authors:  R M Zinkernagel; P C Doherty
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

2.  An in vitro assay for cellular hypersensitivity in man.

Authors:  R E Rocklin; O L Meyers; J R David
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

3.  Liver cell surface localization of hepatitis B antigen and of immunoglobulins in acute and chronic hepatitis and in liver cirrhosis.

Authors:  A Alberti; G Realdi; F Tremolada; G P Spina
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

Review 4.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity.

Authors:  J C Cerottini; K T Brunner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

5.  Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis.

Authors:  A M Cochrane; A Moussouros; A D Thomsom; A L Eddleston; R Wiiliams
Journal:  Lancet       Date:  1976-02-28       Impact factor: 79.321

6.  Immunologic injury in measles virus infection. IV. Antigens modulation and abrogation oflymphocyte lysis of virus-infected cells.

Authors:  M B Oldstone; A Tishon
Journal:  Clin Immunol Immunopathol       Date:  1978-01

7.  Purification and characterization of human liver-specific membrane lipoprotein (LSP).

Authors:  I G McFarlane; B M Wojcicka; G M Zucker; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

8.  Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture.

Authors:  F Paronetto; S Vernace
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

9.  Cell-mediated immunity in acute and chronic hepatitis.

Authors:  J R Wands; J L Perrotto; E Alpert; K J Isselbacher
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

10.  Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis.

Authors:  K R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  20 in total

Review 1.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 2.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 3.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 4.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

5.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

6.  In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

Authors:  M Mondelli; A Alberti; F Tremolada; R Williams; A L Eddleston; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

7.  Functional characterization of peripheral blood lymphocytes in chronic HBsAg carriers.

Authors:  G J Alexander; M Mondelli; N V Naumov; K T Nouriaria; D Vergani; D Lowe; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

Review 8.  Immunological aspects of chronic active hepatitis.

Authors:  S Vento; A L Eddleston
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

9.  Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection.

Authors:  M J Hussain; J Y Lau; R Williams; D Vergani
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

10.  Peripheral blood mononuclear cells and regulatory T cells in acute viral hepatitis.

Authors:  V Barnaba; E Tamburrini; V Laghi; R Cauda; M Levrero; G Ruocco; L Ortona; F Balsano
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.